Abstract
Doxorubicin and ifosfamide are the two most active agents in the treatment of soft-tissue sarcomas. Patients whose tumors have failed these two drugs have very limited systemic therapy options. It is, therefore, important to identify newer drugs with activity against this disease. CI-980 is a synthetic mitotic inhibitor that binds to tubulin at the colchicine binding site and inhibits the polymerization of tubulin and blocks cell cycle progression in mitosis. Given its broad spectrum activity against several solid tumor models in vivo, we decided to perform a phase 2 study of this drug in previously treated soft-tissue sarcomas. A total of 18 eligible and evaluable patients were entered in the first stage of the trial. The median age was 53 yrs (range, 17–72). No objective responses have been noted. Six patients had stable disease after a median of 3.5 cycles of chemotherapy while 12 others had progressive disease. A total of 48 cycles were administered, 42 of which were administered at dose level 0 (4.5 mg/m2/d × 3). 3). The median AGC nadir was 1.2/µl (0.1–4.7) on day 10 and the median platelet nadir was 150,000/µl (31,000–338,000). Twenty cycles were complicated with grade 3–4 neutropenia and two cycles were complicated with FUO. There were no CNS toxicities. One patient had a grade 1 thrombophlebitis in 2 cycles and one other patient had a grade 4 thrombophlebitis in one cycle. In conclusion, CI-980 was well tolerated at this dose and schedule but inactive in soft-tissue sarcomas.
This is a preview of subscription content, log in via an institution to check access.
Similar content being viewed by others
References
Wheeler GP, Bowdon BJ, Werline JA, Adamson DJ, Temple CG: Inhibition of mitosis and anticancer activity against experimental neoplasms by ethyl 5-amino-1,2-dihydro-3-(N-methylanilino) methyl]-pyrido[3,4-b]pyrazin-7-ylcarbamate (NSC 181928). Cancer Res 42:791-798, 1982
Wheeler GP, Bowdon BJ, Temple C Jr, Adamson DJ, Webster J: Biological effects and structure-activity relationships of 1,2-dihydropyrido[3,4]pyrazines. Cancer Res 43:3567-3575, 1983
Bowdon BJ, Waus WR, Wheeler GP, Hain RH, Dansby L, Temple CG: Comparison of 1,2-dihydropyrido[3,4b]pyrazines (1-deaza-7,8-dihydropteridines) with several other inhibitors of mitosis. Cancer Res 47:1621-1626, 1987
Temple C Jr, Rener GA: New anticancer agents: chiral isomers of ethyl (5-amino-1,2dihydro-2methyl-3phenylpyrido[3,4b]pyrazin-7-yl)-carabamate. J Med Chem 32:2089-2092, 1989
de Ines C, Leynadir D, Barasoain I, Peyrot V, Garcia P, Briand C, Rener GA, Temple C Jr: Inhibition of microtubules and cell cycle arrest by a new 1-deaza-7,8-dihydropteridine antitumor drug CI-980, and by its chiral isomer, NSC 613863. Cancer Res 54:75-84, 1994
Waud WR, Leopold WR, Elliott WI, Dykes DJ, Laster WR Jr, Temple CG Jr, Harrison SD Jr, Griswold DP Jr: Antitumor activity of ethyl-5-amino-1,2 dihydro-2-methyl-3phenylpyrido[3,4b]pyrazin-7-yl)-carbamate, 2-hydroxyethanesulfonate hydrate (NSC 370147) against selected tumor systems in culture and in mice. Cancer Res 50:3239- 3244, 1990
Parke-Davis Pharmaceutical Research Division, Warner-Lambert Company. Investigator's Brochure. 1990
Sklarin NT, Benson L, Roca J, Einzig AI, Wiernik PH, Whitfield LR, Lathia C, Kowal C, Grove W: Phase 1 study of CI-980: 24-h infusion schedule. Proc Am Soc Clin Oncol 14:479, 1995
Natale R, Waterhouse D, Grove W, Whitfield LR, Brodfuehrer J, Kowal C: Phase 1 clinical and pharmacokinetic trial of CI-980, a novel mitotic inhibitor. Proc Am Soc Clin Oncol 11:118, 1992
Gutheil J, Van Echo D, Egorin M, Panitch H, Swallow L, O'Hara S, Kearns C: Phase 1 study of CI-980 in patients with refractory malisnancies. Proc Am Assoc Cancer Res 37:164, 1996
Rowinsky EK, Scott Long G, Noe DA, Growchow LB, Bowling MK, Sartorius SE, Donehower RC: Phase 1 and pharmacological study of CI-980, a novel synthetic antimicrotubule agent. Cancer Res 3:401-407, 1997
Parker SL, Tong T, Bolden S, Wingo PA: Cancer Statistics. Ca-A Cancer Journal for Clinicians 47:5-27, 1997
Patel SR, Vadhan-Raj S, Papadopoulos N, Plager C, Burgess MA, Hays C, Benjamin RS: High-dose ifosfamide in bone and soft-tissue sarcomas - Results of phase II and pilot studies - Dose response and schedule dependence. J Clin Oncol 15:2378-2384, 1997
O'Bryan RM, Baker LH, Gottlieb JA, Rivkin SE, Balcerzak SP, Grumet GN, Salmon SE, Moon TE, Hoogstraten B: Dose response evaluation of adriamycin in human neoplasia. Cancer 39:1940-1948, 1977
Patel SR, Vadhan-Raj S, Burgess MA, Papadopoulos NE, Plager C, Jenkins J, Benjamin RS: Dose intensive therapy does improve response rates - Updated results of studies of Adriamycin and Ifosfamide with growth factors in patients with untreated soft-tissue sarcomas. Proc Am Soc Clin Oncol 16:499a, 1997 (abstr 1794)
Pazdur R, Diaz-Canton E, Meyers C, Abbruzzese J, Patt Y, Rivera E, Tourotoglou N, Edwards K, Bready B, Ajani JA: Phase II trial of CI-980 in metastatic colorectal carcinoma patients. Proc Am Soc Clin Oncol 14:208, 1995 (abstr 511)
Verschragen CF, Kudelka AP, Edwards CL, Meyers C, Conrad CA, Freedman RS, Gonzalez de Leon C, Finnegan MB, Hord M, Mante R, Calayag M, Grove W, Kavanagh JJ: Phase II trial of CI-980 in advanced epithelial ovarian carcinoma. Proc Am Soc Clin Oncol 14:271, 1995 (abstr 754)
Author information
Authors and Affiliations
Rights and permissions
About this article
Cite this article
Patel, S.R., Burgess, M.A., Papadopolous, N.E. et al. Phase II study of CI-980 (NSC 635370) in patients with previously treated advanced soft-tissue sarcomas. Invest New Drugs 16, 87–92 (1998). https://doi.org/10.1023/A:1006078930550
Issue Date:
DOI: https://doi.org/10.1023/A:1006078930550